KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Common Equity (2016 - 2025)

Fulgent Genetics' Common Equity history spans 10 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Common Equity fell 2.34% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, down 2.34%, while the annual FY2025 figure was $1.1 billion, 2.34% down from the prior year.
  • Common Equity for Q4 2025 was $1.1 billion at Fulgent Genetics, down from $1.1 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.3 billion in Q1 2022 and bottomed at $801.6 million in Q1 2021.
  • The 5-year median for Common Equity is $1.1 billion (2023), against an average of $1.2 billion.
  • The largest annual shift saw Common Equity surged 957.78% in 2021 before it decreased 11.21% in 2024.
  • A 5-year view of Common Equity shows it stood at $1.2 billion in 2021, then increased by 8.92% to $1.3 billion in 2022, then fell by 10.76% to $1.1 billion in 2023, then decreased by 0.01% to $1.1 billion in 2024, then dropped by 2.34% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Common Equity are $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.1 billion (Q2 2025).